PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 TrialConstructive Type C Meeting Provides Potential Pathway to Accelerated ...

West Pharmaceutical Services just saw its fair value estimate nudged slightly, with the price target essentially steady at ...

PDS Biotech Submits Amended Protocol for Phase 3 VERSATILE-003 Trial Constructive Type C Meeting Provides Potential Pathway to Accelerated Approval of PDS0101 PRINCETON, N.J., Jan. 09, 2026 (GLOBE NEW ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, British Columbia, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Equity-Insider.comNews Commentary – ...

Law firms & in-house legal departments with a presence in the middle east celebrate outstanding achievement within the profession.

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

There are no established treatment options for patients with meningioma recurring after surgery and radiotherapy.

Get all latest & breaking news on Board Meeting. Watch videos, top stories and articles on Board Meeting at moneycontrol.com.

Estimated net revenue over the life of the mine is A$2.6bn ($1.74bn), with a projected average annual EBITDA of around ...

Even though the tax agency's free pilot program is no longer available, there are other free tax filing options this season.

Johnson & Johnson (NYSE:JNJ), a worldwide leader in multiple myeloma therapies, today announced positive topline results from the investigational Phase 3 MajesTEC-9 study of TECVAYLI® ...

The OBBBA flipped the script on planning by permanently raising the lifetime exemption to $15 million and including income ...